ArticleScience progress
TBC1D24 promotes the progression of the breast cancer cells via ARF6/PLD axis under hypoxia.
Article in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cephaeline promotes ferroptosis in breast cancer via p53/SLC7A11/GPX4 axis.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Article
- The Kv10.1 potassium channel, driver of hypoxia-induced EMT and breast cancer cell aggressiveness.Cancer cell international · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveBreast cancer remains a leading cause of cancer-related mortality worldwide, yet the molecular mechanisms underlying its progression are not fully understood. This study aimed to identify novel hypoxia-responsive genes that promote tumor aggressiveness and could serve as prognostic markers or therapeutic targets.MethodsThe integrative bioinformatics analyses were performed using the Gene Expression Profiling Interactive Analysis (GEPIA) and User-Friendly Analysis of Cancer Gene Expression Data (UALCAN) databases to screen for genes associated with survival and tumor stage in breast cancer. Functional validation was conducted in 4th tumor, 1st clone (4T1) and M.D. Anderson-Metastatic Breast-231 (MDA-MB-231) cells under hypoxia. Gene expression was analyzed by quantitative polymerase chain reaction and western blotting. Stemness and tumorigenic potential were evaluated using sphere formation, viability, and proliferation assays.ResultsTBC1 domain family member 24 (TBC1D24) was identified as a hypoxia-responsive gene significantly associated with poor prognosis. Mechanistically, hypoxia-inducible factor-1α upregulated TBC1D24, which in turn increased adenosine diphosphate-ribosylation factor 6 (ARF6) expression and activated the phospholipase D (PLD) signaling pathway. These changes promoted cell viability, proliferation, and stem-like characteristics.ConclusionsTBC1D24 mediates hypoxia-induced tumor progression by activating the ARF6/PLD signaling axis and promoting stemness in breast cancer cells, supporting its potential as a prognostic biomarker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.